Sort   by:  
 Page size 
ProteomicsProteomic analysis of BEAS-2B lung epithelial cells after the introduction of the BRAF V600E mutation using CRISPR/Cas9
To mimic the naturally occurring BRAF V600E mutation in lung cancer, a BRAF V600E knock-in BEAS-2B cell model was established using CRISPR/Cas9. The proteomics analysis was carried out to evaluate the underlying changes at the proteome level. Proteomics analysis revealed significant changes in the p...
ORGANISM(S): Homo sapiens (Human) 
2025-04-22 | PXD058027 | Pride
V600e Lung Amino acid metabolism Nsclc Braf 
TranscriptomicsTranscriptional Response to transgenic BRAF(V600E) in the intestinal epithelium
BRAF(V600E) is a frequent mutation in colon cancer. We have analysed transcriptional effects of BRAF(V600E) in the intestinal epithelium of transgenic mice that harbour an inducible BRAF(V600E) transgene. Mice used in this experiment were compound transgenic for a stem-cell specific Lgr5-EGFP Report...
ORGANISM(S): Mus musculus 
2013-12-31 | E-GEOD-50678 | biostudies-arrayexpress
ProteomicsRICTOR/mTORC2 downregulation in BRAF V600E melanoma cells promotes resistance to BRAF/MEK inhibition
Background Main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF- mutated cutaneous metastatic melanoma (MM) is the development of therapeutic resistance. We aimed to define in this context the specific role of mTORC2, a signaling complex defined by the pr...
ORGANISM(S): Homo sapiens (Human) 
2024-06-22 | PXD050614 | Pride
Targeted therapy Rictor Braf v600e melanoma Mitochondrial metabolism Drug resistance Nampt Mtorc2 
GenomicsOncogenic KRAS(G12V) and BRAF(V600E) in intestinal organoids
Oncogenic KRAS(G12V) and BRAF(V600E) in intestinal organoids
PRJNA474218 | ENA
TranscriptomicsHuman BRAF-V600E melanoma cell lines drug sensitive vs drug resistant
aCGH of human melanoma cell lines comparing parental (drug sensitve) vs isogenic drug resistant-derived subline Two condition experiment: two BRAF-V600E mutant cell lines (drug sensitive - parental baseline) vs two derived sublines after chronic exposure to the MEK inhibitor trametinib (drug resista...
ORGANISM(S): Homo sapiens 
2014-04-21 | E-GEOD-49430 | biostudies-arrayexpress
Genomics3' RNAseq of EGFR mutant lung cancer cell line overexpressing BRAF V600E treated with inhibitors
3' RNAseq of EGFR mutant lung cancer cell line overexpressing BRAF V600E treated with inhibitors
PRJEB47888 | ENA
TranscriptomicsOncogenic KRAS(G12V) and BRAF(V600E) in intestinal organoids
Goals of the study was to compare transcripional and phenotypic response of mouse intestinal organoid cultures to the KRAS(G12V) or BRAF(V600E)oncogenes.
ORGANISM(S): Mus musculus 
2018-06-02 | GSE115234 | GEO
Transcriptomics3' RNAseq of EGFR mutant lung cancer cell line overexpressing BRAF V600E treated with inhibitors
In the human EGFR mutant adenocarcinoma cell line PC9 pBabe empty vector (EV) or BRAF V600E were overexpressed. RNA was extracted from EV, BRAF V600E overexpressing or osimertinib-resistant BRAF V600E expressing cells after 48h treatment with osimertinib, trametinib, a combination of both or vehicle...
ORGANISM(S): Homo sapiens 
2021-10-20 | E-MTAB-11004 | biostudies-arrayexpress
TranscriptomicsExpression profiling of BRAFV600E melanoma cell lines upon RAF inhibition
Microarray expression analysis to identify global changes in transcription in response to RAF inhibition. Genes under RAF control were identified in a panel of BRAFV600E tumor cells, following the short-term inhibition of RAF using a pan-RAF kinase inhibitor, PLX4032 (Plexxikon). For comparison with...
ORGANISM(S): Homo sapiens 
2010-07-18 | E-GEOD-20051 | biostudies-arrayexpress
UnknownMUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
Not available
S-EPMC10408991 | biostudies-literature
Sort   by:  
 Page size